Clinical trials: neoadjuvant therapy, completed
Renal Transplantation
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00214266
- Testing
- Campath 1H®, Rituximab, mycophenolate mofetil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Muscle Invasive Bladder Cancer
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer.
- Trial name
- NCT03773666
- Testing
- Durvalumab, Oleclumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)
- Trial name
- NCT06428487
- Testing
- Prolgolimab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Neoplasms
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
An open-label, randomized three-arm Phase II trial to explore the efficacy of BIBW 2992 as a single agent versus lapatinib versus trastuzumab in patients with HER2-positive treatment-naïve Stage IIIa locally advanced breast…
- Trial name
- NCT00826267
- Testing
- lapatinib, BIBW 2992, trastuzumab
- Where
- 17 sites in United States, Brazil and 2 more
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
In this trial, the objectives are to determine the efficacy and toxicity of induction chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2: A) alone in patients with HNSCC, and to compare…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck
- Trial name
- APA (NCT02573493)
- Testing
- nab-Paclitaxel, Cisplatin, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Actinic Keratosis
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
This study is open to individuals with Actinic Keratoses (skin lesions that have the potential to turn into skin cancer), who are receiving photodynamic therapy (PDT) as part of their clinical care.
- Trial name
- NCT04140292
- Testing
- Photodynamic therapy (PDT), Vitamin D3
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Case Comprehensive Cancer Center
Non-small Cell Lung Cancer (NSCLC)
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
The purpose of this study is to evaluate real-world effectiveness of neoadjuvant nivolumab plus chemotherapy in France.
- Trial name
- NCT06735781
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia (AML)
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00093600
- Testing
- cytarabine, daunorubicin hydrochloride, midostaurin
- Where
- 6 sites in United States, Germany
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Rectal Cancer
Exercise Training in Colorectal Cancer Patients
Neoadjuvant chemoradiotherapy (NACRT) prior to surgery for lower gastrointestinal (colon and rectal) cancer is associated with improved survival, but also adversely affects physical fitness, potentially rendering patients unfit…
- Trial name
- NCT01325909
- Testing
- Exercise programme
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Michelle Mossa
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of nintedanib when given together with cisplatin and docetaxel and to see how well they work in treating patients with previously untreated stage IB-IIIA non-small cell…
- Conditions
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02225405
- Testing
- Cisplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
This trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.
- Trial name
- NCT00136175
- Testing
- Paclitaxel, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed; giving…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00075712
- Testing
- carboplatin, paclitaxel, adjuvant therapy
- Where
- 70 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Royal College of Obstetricians and Gynecologists
Breast Cancer
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Anthracycline-taxane based chemotherapy regimens are recommended mainly by current guidelines for neoadjuvant application of systemic treatment. The addition of other cytotoxic agents, e.g.
- Trial name
- GeparQuinto (NCT00567554)
- Testing
- epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel
- Where
- Germany
- Volunteers
- 2,600 people
- Sponsor
- GBG Forschungs GmbH
Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma
Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer
GastroPET is a prospective, multicenter, non-randomized interventional study evaluating sequential FDG-PET as an early biomarker to guide preoperative treatment in patients with locally advanced resectable oesophago-gastric…
- Conditions
- Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GastroPET (NCT07791329)
- Testing
- FDG-PET
- Where
- Czechia
- Volunteers
- 144 people
- Sponsor
- Masaryk Memorial Cancer Institute
Carcinoma, Squamous Cell, Non-small-cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976362
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus < = 2) and calculation method (bidimensional versus unidimensional).
- Trial name
- NCT04553458
- Testing
- Radiofrequency ablation, Trance-arterial chemoembolization, Liver resection
- Volunteers
- 407 people
- Sponsor
- Sohag University
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00278148
- Testing
- carboplatin, Erlotinib, paclitaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Pennell, MD, PhD
Surgical Site Infection, Pancreatic Neoplasms
Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections
Pancreaticoduodenectomy is associated with high perioperative morbidity, with surgical site infection (SSIs) being one of the most common complications.
- Conditions
- Surgical Site Infection, Pancreatic Neoplasms, Pancreatic Cancer, Chemotherapy Effects
- Trial name
- NCT03021668
- Testing
- Prevena Peel & Place Dressing, Standard Closure of the Surgical Incision
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.